Company Overview
- Website
- shorlaoncology.com
- Phone
- (617) 225-4379
- Employees
- 36
- Founded in
- 2018
- Industry
- Chemical Manufacturing
Financials & Stats
Revenue
$3B
Recent News & Media
Shorla wins FDA nod for ready-to-dilute Tepylute
- Apr 30, 2025
- thepharmaletter.com
Shorla Oncology Announces FDA Approval of TEPYLUTE® 100mg, First and Only Ready-to-Dilute Multi-Dose Vial of Thiotepa to Treat Breast and Ovarian Cancer and Commercial Launch of TEPYLUTE 15mg and 100mg Vials in the U.S.
- Apr 29, 2025
- businesswire.com
Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas
- Apr 29, 2025
- oncnursingnews.com
FDA Approves Multi-Dose Vial of Thiotepa for Breast and Ovarian Cancer
- Apr 29, 2025
- onclive.com
Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams
- Mar 4, 2025
- businesswire.com
FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers
- Nov 27, 2024
- pmlive.com
Company Leadership
Shorla Oncology Tech Stack
Companies Similar to Shorla Oncology
Analyze industry trends and opportunities by examining competitors and companies comparable to Shorla Oncology, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 3M | Houston, TX | 2016 | ||
| 3M | 21 | New York, NY | ||
| 3M | 6 | Chicago, IL | 2003 | |
| 3M | 16 | Tampa, FL | 2006 | |
| 3M | 7 | Phoenix, AZ |